Sagimet Biosciences (SGMT) Q4 2025 earnings summary

Executive summary

• Completed Phase 1 pharmacokinetic clinical trial of denifanstat and resmetirom combination, showing good tolerability and no safety signals in MASH patients.

• Positive topline results from open-label Phase 3 trial of denifanstat in moderate to severe acne in China, supporting NDA acceptance by Chinese NMPA.

• Secured global, exclusive license to TAPI's innovative forms of resmetirom API for future combination development.

• Ongoing first-in-human Phase 1 trial of FASN inhibitor TVB-3567 for acne indication.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $113.1 million as of December 31, 2025.

• Research and development expense was $39.1 million for 2025, up slightly from $38.4 million in 2024.

• General and administrative expense was $17.8 million for 2025, compared to $16.0 million in 2024.

• Net loss for 2025 was $51.0 million, compared to $45.6 million in 2024.

Outlook and guidance

• Phase 2 proof-of-concept trial of denifanstat/resmetirom combination in F4 MASH patients planned for 2H 2026, pending regulatory consultation.

• Anticipates starting Phase 2 clinical trial with TVB-3567 in moderate to severe acne patients in 2026, subject to Phase 1 completion and regulatory input.